Ñî¹óåú´«Ã½Ò•îl

SARS-CoV-2-associated deaths among persons 21 years of age occurred predominantly among Black (non-Hispanic) and Hispanic persons, male patients, and older adolescents. The most commonly reported underlying conditions were obesity, asthma, and developmental disorders. Decedents with coronavirus disease 2019 were more likely than those with MIS-C to have underlying medical conditions. (McCormick et al, 11/1)

We found a clear association between COVID-19 vaccination and specific immunoglobulin concentrations in HM. This effect was more pronounced when lactation periods exceeded 23 months. The influence of the lactation period on immunoglobulins was specific and independent of other variables. (Ramirez et al, 11/1)

Cancer patients who received systemic treatment like chemotherapy or radiation in the 3 months before testing positive for COVID-19 were at increased risk of death, admission to an intensive care unit (ICU), and hospitalization, according to a study yesterday in JAMA Oncology. Researchers from the University of Texas MD Anderson Cancer Center analyzed the clinical outcomes in the electronic health records of 507,307 US adults with and without a diagnosis of cancer who tested positive for COVID-19 from Jan 1 to Dec 31, 2020. (10/29)

Among children with community-acquired pneumonia (CAP) who were discharged from the hospital within 48 hours but required further outpatient treatment, a lower dose of oral amoxicillin was non-inferior to a higher dose, and a 3-day duration was non-inferior to 7 days, according to the results of a randomized clinical trial published today in JAMA. (11/2)

In 2008, over-the-counter cough and cold medications (CCMs) underwent labeling changes in response to safety concerns, including fatalities, reported in children exposed to CCMs. ... Pediatric fatalities associated with CCMs occurred primarily in young children after deliberate medication administration with nontherapeutic intent by a caregiver. (Halmo, 11/1)

Findings of this case series cohort study indicate a slightly increased risk of Guillain-Barré syndrome during the 42 days following RZV vaccination in the Medicare population, with approximately 3 excess Guillain-Barré syndrome cases per million vaccinations. Clinicians and patients should be aware of this risk, while considering the benefit of decreasing the risk of herpes zoster and its complications through an efficacious vaccine, as risk-benefit balance remains in favor of vaccination. (Goud, 11/1)